FB Pixel no script
MENU
KrASIA

China

Insights

After Hengrui’s USD 500 million deal with GSK, which biotech firms are next in line?

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

6 mins read
  • Collaboration was central to shaping the Li i8’s defining strengths.

    Features

    Li Auto overcame supply chain snags to build the Li i8, but will that be enough?

    6 mins read

Most Recent

See All